This is an archive article published on March 16, 2021
Premium

Explained: The controversy around Oxford-AstraZeneca’s vaccine for Covid-19

The vaccine, which is being produced and distributed in India as Covishield by Serum Institute of India (SII), is also expected to undergo a review by the nodal adverse event following immunisation body this week.

A doctor prepares the AstraZeneca vaccine at a Pharmacy in Edgeware, London, Tuesday, March 16, 2021, as Britain continues use of the vaccine. (AP Photo/Frank Augstein)A doctor prepares the AstraZeneca vaccine at a Pharmacy in Edgeware, London, Tuesday, March 16, 2021, as Britain continues use of the vaccine. (AP Photo/Frank Augstein)
8 min readNew DelhiMar 17, 2021 10:56 AM IST First published on: Mar 16, 2021 at 07:58 PM IST

Amid rising concerns over its safety and efficacy, two more European countries Tuesday suspended the use of Oxford-AstraZeneca’s Covid-19 vaccine in a further blow to the European Union’s vaccination drive. This comes even as the EU’s health authority said the benefits of the vaccine outweigh the risks.

Sweden and Latvia joined the list of other European nations that have halted the use of the British drugmaker’s Covid-19 vaccine after reports that some people who got a dose developed blood clots.

Advertisement

The vaccine, which is being produced and distributed in India as Covishield by Serum Institute of India (SII), is also expected to undergo a review by the nodal adverse event following immunisation body this week.

Latest Comment
Post Comment
Read Comments